A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer.
Publication Title
J Thorac Dis
Document Type
Article
Publication Date
6-30-2024
Keywords
Nintedanib; adenocarcinoma; multikinase inhibitor; non-small cell lung cancer (NSCLC); vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI).; washington; seattle; swedish
Abstract
BACKGROUND: Nintedanib is a small molecule tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR). The purpose of the study was to evaluate the response rate for patients with advanced non-small cell lung cancer (NSCLC) with mutations in
METHODS: Patients with advanced NSCLC previously treated with platinum-doublet chemotherapy with the above mutations were enrolled. Exclusion criteria included necrotic tumors with invasion of blood vessels, history of recent thromboembolic events, increased risk of bleeding or thrombosis, myocardial infarction, and weight loss >10% within past 6 months. Nintedanib was administered at a dose of 200 mg orally twice daily until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Secondary endpoints included progression-free survival (PFS) and correlating outcomes with specific mutations. This study was registered with ClinicalTrials.gov, number NCT02299141.
RESULTS: Between 2015 and 2019, 20 patients were enrolled with a median age was 66 years, 15 (75%) were females, 15 (75%) had adenocarcinoma, and 17 patients had a
CONCLUSIONS: In this pilot study in heavily pretreated and molecularly selected patients with metastatic NSCLC, nintedanib showed modest activity.
Clinical Institute
Cancer
Specialty/Research Institute
Oncology
Specialty/Research Institute
Pulmonary Medicine
DOI
10.21037/jtd-23-1717
